Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Ani Pharmaceuticals (ANIP) over the last 14 years, with Q3 2025 value amounting to $12.5 million.

  • Ani Pharmaceuticals' Other Non-Current Assets rose 901.08% to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year increase of 901.08%. This contributed to the annual value of $12.2 million for FY2024, which is 122.6% up from last year.
  • Per Ani Pharmaceuticals' latest filing, its Other Non-Current Assets stood at $12.5 million for Q3 2025, which was up 901.08% from $8.2 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Other Non-Current Assets ranged from a high of $16.1 million in Q3 2023 and a low of $5.0 million during Q1 2021
  • Moreover, its 5-year median value for Other Non-Current Assets was $11.4 million (2022), whereas its average is $9.9 million.
  • Per our database at Business Quant, Ani Pharmaceuticals' Other Non-Current Assets soared by 17141.62% in 2023 and then crashed by 3581.88% in 2025.
  • Ani Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $5.0 million in 2021, then soared by 127.17% to $11.4 million in 2022, then increased by 6.26% to $12.1 million in 2023, then increased by 1.23% to $12.2 million in 2024, then rose by 2.27% to $12.5 million in 2025.
  • Its Other Non-Current Assets stands at $12.5 million for Q3 2025, versus $8.2 million for Q2 2025 and $10.3 million for Q1 2025.